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Abstract
A 67-year-old patient died of Legionella bozemanii 
pneumonia with negative urinary antigen and negative 
serology. Cystic lesions in pneumonia of unknown origin 
should lead to the differential diagnosis of L. bozemanii 
infections.
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A 67-year-old woman was admitted to the medical inten-
sive care unit (ICU) for progressive acute respiratory dis-
tress with cardiac and renal failure and suspected pneu-
monia. On admission, her temperature was 37.6 °C, white 
blood count (WBC) 10.8 × 109/l, C-reactive protein (CRP) 
57 mg/l, and creatinine 350 μmol/l. A chest X-ray revealed 
bilateral infiltrates of the lung, pleural effusions, and car-
diomegaly. Electrocardiogram, cardiac enzymes and tropo-
nin levels were unremarkable.
Since 1980, she suffered from biopsy-proven medias-
tinal sarcoidosis. In addition, she had a 9-year history of 
systemic lupus erythematosus (SLE) with progressive re-
nal failure despite prednisone and nivaquin treatment. In 
January 2002, a CT scan of the lung was performed due 
to weight loss of 16 kg within the last 6 months showing 
small cystic lesions in the left lower lobe. Her medications 
included amlodipinum and losartan.
She was admitted to the hospital for cardiovascular 
support and was treated with ceftriaxone and clarithromy-
cin for suspected pneumonia. However, microbiological in-
vestigation including cultures of sputum, blood, urine and 
pleural fluid were negative. Clarithromycin was discon-
tinued after clinical improvement and a negative urinary 
antigen test for Legionella pneumophila (NOW® Legio-
nella Urinary Antigen Test, Binax, Inc., Scarborough, ME, 
USA). Two days later, the pulmonary function continued 
to decrease, and corticosteroids were added for suspected 
reactivation of sarcoidosis and/or SLE.
Ceftriaxone was replaced after 12 days by piperacil-
lin/tazobactam (P/T) for suspected superinfection dur-
ing ICU stay. Despite broad-spectrum antimicrobial and 
corticosteroid therapy, clinical signs and symptoms dete-
riorated, CRP and WBC rose, and thrombocytes dropped. 
One day later, the patient required emergency intubation 
because of acute respiratory distress syndrome (ARDS). 
CRP was 325 mg/l, WBC 18 × 109/l. A CT scan continued 
to reveal progressing infiltrates in both lungs. A bronchial 
aspirate grew one colony of Aspergillus fumigatus that was 
interpreted as contamination. Antibiotics were switched 
from P/T to meropenem due to continuous deterioration 
of the clinical status. Severe thrombocytopenia of unknown 
etiology delayed lung biopsy for 4 weeks, which demon-
strated interstitial fibrosing pneumonia with accumula-
tion of intra-alveolar foamy macrophages. Few colonies of 
A. fumigatus grew from biopsy material suggesting pulmo-
nary invasive aspergillosis. Therefore, liposomal amphoter-
icin B was added. Despite broad-spectrum antimicrobial 
therapy, respiratory failure developed. On repeat chest X-
ray and CT scan, new cavitary lesions became prominent 
in the right upper lobe. Because the histology of the lung 
did not show any signs of invasive aspergillosis, cyclospo-
sphamid was added for possible necrotising pulmonary 
vasculitis. A repeated urinary antigen test and a serology 
for Legionella pneumophila (Legionella pneumophila [1–8] 
IFA, Meridian Bioscience, Cincinnati, OH, USA) remained 
negative. However, L. bozemanii grew from cultures of the 
lung biopsy and Dieterle stain demonstrated intra- and 
extracellular rods (Figure 1). Clarithromycin was reestab-
lished, but the patient deceased 2 days later after start of 
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treatment. Identification of the strain was confirmed by 
the Swiss Legionella reference laboratory. The source of 
L. bozemanii remained unknown: samples from hospital 
faucets and from the shower and faucets of patient’s home 
proved negative for Legionella spp.
L. bozemanii is an infrequent cause of legionellosis, 
even though endemic in water and soil, also in Europe. 
L. bozemanii infections in immunocompromised patients 
typically produce cavitary lung lesions [3, 4].
Immunocompromised patients with cystic lesions in 
the upper lobes frequently suffer from tuberculosis, but 
other diagnoses should be considered such invasive asper-
gillosis or an autoimmune disease [5]. Clinicians should be 
aware on recent reports from patients after transplantation 
or AIDS with L. bozemanii infections [3, 6]. Diagnosis of 
L. bozemanii is difficult: commonly used urinary antigen 
tests for Legionella and serological kits fail to consistently 
detect L. bozemanii [7]. The urinary antigen for Legionella 
is targeted against L. pneumophila serotype 1, and was re-
petitively negative in the present case, challenging a recent 
report [8]. None of the commercially available serological 
kits are able to identify antibodies to L. bozemanii with 
high sensitivity and remained negative in this case. Even 
microbiologic cultures using media for Legionella may be 
false negative since most culture media for Legionella con-
tain cefamandole, a drug being active against L. bozemanii 
in vitro [9] in contrast to other species of Legionella.
L. bozemanii should be included in the differential 
diagnosis of cystic lung lesions in the lower lobes, when 
more frequently observed diagnoses such as tuberculo-
sis and non-infectious diseases have been ruled out [10]. 
Appropriate specimens with specific information to the 
microbiology laboratory are crucial to isolate L. bozemanii. 
Lung biopsies should be investigated for Legionella e.g., 
by the Dieterle stain in cystic lesions of unknown origin. 
Today, antimicrobial treatment with a quinolone may be 
preferred to macrolides in the immunocompromised host 
[5, 11, 12]. In conclusion, clinical awareness of this rare 
pathogen and an interdisciplinary approach to immuno-
compromised patients presenting with cavitary pneumo-
nia of unknown origin are crucial for guided treatment 
to decrease mortality of this severe disease. Diagnosis of 
L. pneumophila serogroup 1 has been facilitated by the 
rapid urinary antigen test. However, only cultures for 
Legionella are able to detect other Legionella species 
and should not be abandoned, particularly in severely ill 
patients.
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Figure 1. Section of the open lung biopsy (left lower lobe) showing 
alveolar foam cells and macrophages with slender intra- and
extracellular rods (arrows ). (Dieterle stain; magnification 630×).
